Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M466Revenue $M42.2Net Margin (%)-13.4Z-Score5.6
Enterprise Value $M353EPS $0.8Operating Margin %-10.6F-Score5
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-12.4Higher ROA y-yN
Price/Book3.810-y EBITDA Growth Rate %0Quick Ratio4.6Cash flow > EarningsY
Price/Sales4.75-y EBITDA Growth Rate %0Current Ratio4.7Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %-193.8ROA % (ttm)-7.6Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-10.7Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M20.7ROI % (ttm)21.6Gross Margin Increase y-yY

Gurus Latest Trades with HPTX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HPTXJoel Greenblatt 2014-09-30 Buy $21.96 - $27.64
($24.83)
$ 22.5-9%New holding, 18109 sh.18,109
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HPTX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
HPTX Joel Greenblatt 2014-09-3018,1090.090New Buy
Premium Most recent portfolio changes are included for Premium Members only!


HPTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Scharschmidt Bruce FrederickSVP & Chief Medical Officer 2014-07-02Sell200$28-19.64view
SANDELL SCOTT D10% Owner 2014-06-06Sell1,430$5.54306.14view
DRANT RYAN D10% Owner 2014-06-06Sell1,134$26.9-16.36view
BARRETT M JAMES10% Owner 2014-06-06Sell1,430$26.88-16.29view
BASKETT FOREST10% Owner 2014-06-06Sell1,377$26.9-16.36view
BARRIS PETER J10% Owner 2014-06-06Sell1,134$26.9-16.36view
KOLLURI KRISHNA KITTU10% Owner 2014-06-06Sell120$27.19-17.25view
SOFINNOVA VENTURE PARTNERS VII10% Owner 2014-06-04Sell417,747$27.7-18.77view
HEALY JAMESDirector 2014-06-04Sell417,747$27.7-18.77view
Nash Christine ASVP & Chief Commercial Officer 2014-03-06Sell5,100$29.05-22.55view

Press Releases about HPTX :

    Quarterly/Annual Reports about HPTX:

    News about HPTX:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    Hyperion Therapeutics Added to Nasdaq Biotechnology Index (NBI) Dec 18 2014
    Hyperion Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference Dec 04 2014
    HYPERION THERAPEUTICS INC Financials Nov 14 2014
    Hyperion Therapeutics (HPTX) Downgraded From Hold to Sell Nov 14 2014
    Hyperion Therapeutics to Present at the Jefferies 2014 Global London Healthcare Conference Nov 13 2014
    Hyperion Therapeutics to Present at the Jefferies 2014 Global London Healthcare Conference Nov 13 2014
    Hyperion tops 3Q revenue forecasts Nov 06 2014
    Hyperion tops 3Q revenue forecasts Nov 06 2014
    Hyperion Therapeutics Inc Earnings Call scheduled for 4:05 pm ET today Nov 06 2014
    Hyperion Therapeutics Announces Third Quarter 2014 Financial Results Nov 06 2014
    HYPERION THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change... Nov 06 2014
    Hyperion Therapeutics Announces Third Quarter 2014 Financial Results Nov 06 2014
    Q3 2014 Hyperion Therapeutics Inc Earnings Release - After Market Close Nov 06 2014
    Street Talk: Downgrade for Deans Nov 03 2014
    Coverage initiated on Hyperion Therapeutics by ROTH Capital Nov 03 2014
    Hyperion Therapeutics to Report Third Quarter 2014 Financial Results After Market on November 6,... Oct 31 2014
    Hyperion Therapeutics to Report Third Quarter 2014 Financial Results After Market on November 6,... Oct 31 2014
    Avanir (AVNR) Presents Detailed Phase II Data on AVP-923 Oct 14 2014
    Hyperion, Clal Biotech resolve dispute over diabetes drug Oct 07 2014
    Hyperion Therapeutics and Clal Biotechnology Industries Ltd. Enter Into Interim Agreement Oct 07 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK